DeutschNewstral
Tetsuo Nakayama
Japan approves Pfizer shot for children age 5 to 11 as omicron spreads among cohortThe Japan Times- Japan panel approves Pfizer shot for children age 5 to 11 as omicron spreadsThe Japan Times
- The ins and outs of Japan’s COVID-19 booster shot rolloutThe Japan Times
- Could omicron be the beginning of the end of the COVID-19 pandemic?The Japan Times
- Tokyo researchers developing ‘dream’ COVID-19 vaccine that gives protection for lifeThe Japan Times
- Japan’s COVID-19 booster shot drive kicks off with health care workersThe Japan Times
- Boosters, logistics and shots for kids: Challenges remain as Japan hits vaccine turning pointThe Japan Times
- Japan to allow COVID-19 booster shots six months after second doseThe Japan Times
- Pfizer to seek OK for use of COVID-19 shot in children in Japan age 5 to 11The Japan Times
- Japan may recommend Pfizer’s COVID-19 shot over Moderna’s for men under 30The Japan Times
- More cities in Japan prioritizing COVID-19 vaccines for pregnant womenThe Japan Times
- Health ministry panel approves AstraZeneca’s vaccine for people 40 and overThe Japan Times
- Even with delta surging, experts say two vaccine doses are enough for nowThe Japan Times
Biotech startup envisions vaccinations for billions in Japanstaradvertiser.com- How to secure vaccines for billions? One Japanese biotech startup has an idea.The Japan Times
With 1.1% of people vaccinated, Japan lags in the developed worldMerced Sun-Star- With 1.1% of people vaccinated, Japan lags the developed worldThe Japan Times
- Japan’s slow vaccine rollout pushes back recovery time frameThe Japan Times
- Japanese firms launch domestic clinical trials for COVID-19 vaccinesThe Japan Times
- Japan drugmakers struggle to keep pace in COVID-19 medicine developmentThe Japan Times
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.